Drugs / convalescent plasma
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT04438057 Comparator | Aug 2020 | COVID-19 | Metro Infectious Disease Consultants | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | convalescent plasma | “convalescent plasma” NCT04438057 ↗ |
| Known as | CCP | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04438057 ↗ |
| Modality | Protein / enzyme biologic | “investigational convalescent plasma” NCT04438057 ↗ |
| Route | Intravenous | “The plasma will be infused in an outpatient infusion center” NCT04438057 ↗ |